243 related articles for article (PubMed ID: 7712469)
1. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
Fan S; Smith ML; Rivet DJ; Duba D; Zhan Q; Kohn KW; Fornace AJ; O'Connor PM
Cancer Res; 1995 Apr; 55(8):1649-54. PubMed ID: 7712469
[TBL] [Abstract][Full Text] [Related]
2. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard.
Fan S; Chang JK; Smith ML; Duba D; Fornace AJ; O'Connor PM
Oncogene; 1997 May; 14(18):2127-36. PubMed ID: 9174048
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
Fan S; el-Deiry WS; Bae I; Freeman J; Jondle D; Bhatia K; Fornace AJ; Magrath I; Kohn KW; O'Connor PM
Cancer Res; 1994 Nov; 54(22):5824-30. PubMed ID: 7954409
[TBL] [Abstract][Full Text] [Related]
4. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin.
Smith ML; Kontny HU; Zhan Q; Sreenath A; O'Connor PM; Fornace AJ
Oncogene; 1996 Nov; 13(10):2255-63. PubMed ID: 8950993
[TBL] [Abstract][Full Text] [Related]
5. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.
Fan S; Cherney B; Reinhold W; Rucker K; O'Connor PM
Clin Cancer Res; 1998 Apr; 4(4):1047-54. PubMed ID: 9563901
[TBL] [Abstract][Full Text] [Related]
6. Preferential radiosensitization in p53-mutated human tumour cell lines by pentoxifylline-mediated disruption of the G2/M checkpoint control.
Strunz AM; Peschke P; Waldeck W; Ehemann V; Kissel M; Debus J
Int J Radiat Biol; 2002 Aug; 78(8):721-32. PubMed ID: 12194756
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
[TBL] [Abstract][Full Text] [Related]
9. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II).
Husain A; Rosales N; Schwartz GK; Spriggs DR
Gynecol Oncol; 1998 Jul; 70(1):17-22. PubMed ID: 9698467
[TBL] [Abstract][Full Text] [Related]
10. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
Wang Q; Fan S; Eastman A; Worland PJ; Sausville EA; O'Connor PM
J Natl Cancer Inst; 1996 Jul; 88(14):956-65. PubMed ID: 8667426
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage.
Smith ML; Chen IT; Zhan Q; O'Connor PM; Fornace AJ
Oncogene; 1995 Mar; 10(6):1053-9. PubMed ID: 7700629
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: roles of p53 and caspase activation.
Liu Y; McKalip A; Herman B
J Cell Biochem; 2000 May; 78(2):334-49. PubMed ID: 10842327
[TBL] [Abstract][Full Text] [Related]
13. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells.
Russell KJ; Wiens LW; Demers GW; Galloway DA; Plon SE; Groudine M
Cancer Res; 1995 Apr; 55(8):1639-42. PubMed ID: 7712467
[TBL] [Abstract][Full Text] [Related]
15. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
[TBL] [Abstract][Full Text] [Related]
16. Absence of a radiation-induced first-cycle G1-S arrest in p53+ human tumor cells synchronized by mitotic selection.
Nagasawa H; Keng P; Maki C; Yu Y; Little JB
Cancer Res; 1998 May; 58(9):2036-41. PubMed ID: 9581850
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function.
Bracey TS; Williams AC; Paraskeva C
Clin Cancer Res; 1997 Aug; 3(8):1371-81. PubMed ID: 9815821
[TBL] [Abstract][Full Text] [Related]
18. Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation.
Tsang NM; Nagasawa H; Li C; Little JB
Oncogene; 1995 Jun; 10(12):2403-8. PubMed ID: 7784090
[TBL] [Abstract][Full Text] [Related]
19. A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers.
Seth P; Katayose D; Li Z; Kim M; Wersto R; Craig C; Shanmugam N; Ohri E; Mudahar B; Rakkar AN; Kodali P; Cowan K
Cancer Gene Ther; 1997; 4(6):383-90. PubMed ID: 9408609
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand.
Koivusalo R; Krausz E; Ruotsalainen P; Helenius H; Hietanen S
Cancer Res; 2002 Dec; 62(24):7364-71. PubMed ID: 12499281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
